China Pharma Holdings (CPHI) Total Current Liabilities (2010 - 2026)

China Pharma Holdings (CPHI) has reported Total Current Liabilities for 17 consecutive years, with $7.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 46.3% year-over-year to $7.7 million; the trailing twelve-month figure through Jun 2026 stood at $7.7 million (up 46.3% YoY), and the FY2025 full-year result was $7.4 million, up 47.5% from the prior year.
• Total Current Liabilities climbed to $7.7 million in Q2 2026 per CPHI's latest filing, from $7.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $12.7 million in Q4 2022 and bottomed at $4.7 million in Q2 2024.
• Historically, Total Current Liabilities has averaged $7.8 million across 5 years, with a median of $7.2 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities tumbled 55.32% in 2024, then surged 47.5% in 2025.
• Over 5 years, Total Current Liabilities stood at $12.7 million in 2022, then plunged by 46.46% to $6.8 million in 2023, then slipped by 26.44% to $5.0 million in 2024, then surged by 47.5% to $7.4 million in 2025, then increased by 3.8% to $7.7 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $7.7 million, $7.3 million, and $7.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.